Quo vadis radiotherapy? Technological advances and the rising problems in cancer management

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Allen, Barry J ^a   Bezak, Eva ^b,c   Marcu, Loredana G ^b,c,d  

^a St George Cancer Care Centre   (Australia)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d UNIVERSITY OF ORADEA   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ADVANCED CANCER; ANISOTROPY; BRAIN METASTASIS; CANCER CONTROL; CANCER INHIBITION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SIZE; COST BENEFIT ANALYSIS; EXTERNAL BEAM RADIOTHERAPY; GLIOBLASTOMA; HADRON; HEAD AND NECK CANCER; HUMAN; INTENSITY MODULATED RADIATION THERAPY; ION THERAPY; LUNG CANCER; MOLECULAR IMAGING; NEUTRON CAPTURE THERAPY; NEUTRON THERAPY; PANCREAS CANCER; PERSONALIZED MEDICINE; PHOTON THERAPY; POSITRON EMISSION TOMOGRAPHY; PRIMARY TUMOR; PROSTATE CANCER; PROTON THERAPY; RADIATION RESPONSE; RADIOISOTOPE THERAPY; RADIOSENSITIVITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYSTEMATIC REVIEW (TOPIC); UVEA MELANOMA; ECONOMICS; NEOPLASMS; TRENDS; NEOPLASM; RADIOTHERAPY;

COST-BENEFIT ANALYSIS; HUMANS; NEOPLASMS; RADIOTHERAPY;

EID: 84879403120     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/749203     Document Type: Review

References (37)

1. Kolata G., Playing it Safe in Cancer Research 2009 The New York Times
2. http://www.nytimes.com/imagepages/2009/06/28/health/28cancer.grafic. ready.html
3. Burnet N., Thomas S., Burton K., Jefferies S., Defining the tumour and target volumes for radiotherapy. Cancer Imaging 2004 42 153 161
4. Miralbell R., Lomax A., Cella L., Schneider U., Potential reduction of the incidence of radiation-induced second cancers by using proton beams in the treatment of pediatric tumors. International Journal of Radiation Oncology Biology Physics 2002 54 3 824 829 2-s2.0-0036836138
5. Clair W., Adams J., Bues M., Advantage of protons compared to conventional X-ray or IMRT in the treatment of a pediatric patient with medulloblastoma. International Journal of Radiation Oncology Biology Physics 2004 48 727 734 (Pubitemid 38221128)
6. Kattan M. W., Stapleton A. M., Wheeler T. M., Scardino P. T., Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma. Cancer 1997 79 528 537 (Pubitemid 27051778)
7. Partin A. W., Kattan M. W., Subong E. N. P., Walsh P. C., Wojno K. J., Oesterling J. E., Scardino P. T., Pearson J. D., Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: a multi-institutional update. Journal of the American Medical Association 1997 277 18 1445 1451 2-s2.0-0030913315 (Pubitemid 27208886)
8. Allen B. J., Raja C., Rizvi S., Li Y., Tsui W., Graham P., Thompson J. F., Reisfeld R. A., Kearsley J., Intralesional targeted alpha therapy for metastatic melanoma. Cancer Biology and Therapy 2005 4 12 1318 1324 2-s2.0-31144463014 (Pubitemid 43131174)
9. Schulz-Ertner D., Tsujii H., Particle radiation therapy using proton and heavier ion beams. Journal of Clinical Oncology 2007 25 8 953 964 2-s2.0-33947535720 10.1200/JCO.2006.09.7816 (Pubitemid 350002861)
10. Grutters J. P. C., Kessels A. G. H., Pijls-Johannesma M., De Ruysscher D., Joore M. A., Lambin P., Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: a meta-analysis. Radiotherapy and Oncology 2010 95 1 32 40 2-s2.0-77950312339 10.1016/j.radonc.2009.08.003
11. Ask A., Björk-Eriksson T., Zackrisson B., Blomquist E., Glimelius B., The potential of proton beam radiation therapy in head and neck cancer. Acta Oncologica 2005 44 8 876 880 2-s2.0-28844448270 10.1080/02841860500355991 (Pubitemid 41780113)
12. Glimelius B., Ask A., Bjelkengren G., Björk-Eriksson T., Blomquist E., Johansson B., Karlsson M., Zackrisson B., Number of patients potentially eligible for proton therapy. Acta Oncologica 2005 44 8 836 849 2-s2.0-28844435764 10.1080/02841860500361049 (Pubitemid 41780109)
13. Glimelius B., Montelius A., Proton beam therapy-do we need the randomised trials and can we do them? Radiotherapy and Oncology 2007 83 2 105 109 2-s2.0-34248637621 10.1016/j.radonc.2007.04.009 (Pubitemid 46776924)
14. Lodge M., Pijls-Johannesma M., Stirk L., Munro A. J., De Ruysscher D., Jefferson T., A systematic literature review of the clinical and cost-effectiveness of hadron therapy in cancer. Radiotherapy and Oncology 2007 83 2 110 122 2-s2.0-34248656498 10.1016/j.radonc.2007.04.007 (Pubitemid 46776922)
15. Allen B. J., Abbas Rizvi S. M., Qu C. F., Smith R. C., Targeted alpha therapy approach to the management of pancreatic cancer. Cancers 2011 3 2 1821 1843 2-s2.0-79959769784 10.3390/cancers3021821
16. Blattmann C., Oertel S., Schulz-Ertner D., Rieken S., Haufe S., Ewerbeck V., Unterberg A., Karapanagiotou-Schenkel I., Combs S. E., Nikoghosyan A., Bischof M., Jäkel O., Huber P., Kulozik A. E., Debus J., Non-randomized therapy trial to determine the safety and efficacy of heavy ion radiotherapy in patients with non-resectable osteosarcoma. BMC Cancer 2010 10, article 96 2-s2.0-77951196395 10.1186/1471-2407-10-96
17. Tsujii H., Mizoe J. E., Kamada T., Baba M., Kato S., Kato H., Tsuji H., Yamada S., Yasuda S., Ohno T., Yanagi T., Hasegawa A., Sugawara T., Ezawa H., Kandatsu S., Yoshikawa K., Kishimoto R., Miyamoto T., Overview of clinical experiences on carbon ion radiotherapy at NIRS. Radiotherapy and Oncology 2004 73 2, supplement S41 S49 2-s2.0-21444447811 (Pubitemid 41219112)
18. Mizoe J. E., Tsujii H., Hasegawa A., Yanagi T., Takagi R., Kamada T., Tsuji H., Takakura K., Phase I/II clinical trial of carbon ion radiotherapy for malignant gliomas: combined X-ray radiotherapy, chemotherapy, and carbon ion radiotherapy. International Journal of Radiation Oncology Biology Physics 2007 69 2 390 396 2-s2.0-34548484610 10.1016/j.ijrobp.2007.03.003 (Pubitemid 47380082)
19. Kano M., Yamada S., Hoshino I., Murakami K., Akutsu Y., Sakata H., Nishimori T., Usui A., Miyazawa Y., Kamada T., Tsujii H., Matsubara H., Effects of carbon-ion radiotherapy combined with a novel histone deacetylase inhibitor, cyclic hydroxamic-acid-containing peptide 31 in human esophageal squamous cell carcinoma. Anticancer Research 2009 29 11 4433 4438 2-s2.0-75149186089
20. http://ptcog.web.psi.ch/
21. Barth R. F., Joensuu H., Boron neutron capture therapy for the treatment of glioblastomas and extracranial tumours: as effective, more effective or less effective than photon irradiation? Radiotherapy and Oncology 2007 82 2 119 122 2-s2.0-33847215805 10.1016/j.radonc.2007.01.010
22. Henriksson R., Capala J., Michanek A., Boron neutron capture therapy (BNCT) for glioblastoma multiforme: a phase II study evaluating a prolonged high-dose of boronophenylalanine (BPA). Radiotherapy and Oncology 2008 88 2 183 191
23. Wittig A., Collette L., Appelman K., Bührmann S., Jäckel M. C., Jöckel K. H., Schmid K. W., Ortmann U., Moss R., Sauerwein W. A. G., EORTC trial 11001: distribution of two 10B-compounds in patients with squamous cell carcinoma of head and neck, a translational research/phase 1 trial. Journal of Cellular and Molecular Medicine 2009 13 8 B 1653 1665 2-s2.0-72949106920 10.1111/j.1582-4934.2009.00856.x
24. Kneifel S., Cordier D., Good S., Ionescu M. C. S., Ghaffari A., Hofer S., Kretzschmar M., Tolnay M., Apostolidis C., Waser B., Arnold M., Mueller-Brand J., Maecke H. R., Reubi J. C., Merlo A., Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-substance P. Clinical Cancer Research 2006 12 12 3843 3850 2-s2.0-33745697736 10.1158/1078-0432.CCR-05-2820 (Pubitemid 44000266)
25. Allen B. J., Raja C., Rizvi S., Song E. Y., Graham P., Tumour anti-vascular alpha therapy: a mechanism for the regression of solid tumours in metastatic cancer. Physics in Medicine and Biology 2007 52 13 L15 L19 2-s2.0-34250363163 10.1088/0031-9155/52/13/L01 (Pubitemid 46908610)
26. Allen B. J., Future prospects for targeted alpha therapy. Current Radiopharmaceuticals 2011 4 4 336 342
27. Jiang T., Olson E. S., Nguyen Q. T., Roy M., Jennings P. A., Tsien R. Y., Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proceedings of the National Academy of Sciences of the United States of America 2004 101 51 17867 17872 2-s2.0-11144229887 10.1073/pnas.0408191101 (Pubitemid 40051978)
28. Foerg C., Merkle H. P., On the biomedical promise of cell penetrating peptides: limits versus prospects. Journal of Pharmaceutical Sciences 2008 97 1 144 162 2-s2.0-38349174536 10.1002/jps.21117
29. Etzioni R., Urban N., Ramsey S., McIntosh M., Schwartz S., Reid B., Radich J., Anderson G., Hartwell L., The case for early detection. Nature Reviews Cancer 2003 3 4 243 252 2-s2.0-0037648348 (Pubitemid 37328860)
30. Tursz T., Andre F., Lazar V., Lacroix L., Soria J. C., Implications of personalized medicine-perspective from a cancer center. Nature Reviews Clinical Oncology 2011 8 3 177 183 2-s2.0-79952423736 10.1038/nrclinonc.2010.222
31. Bussink J., Kaanders J. H. A. M., Van Der Graaf W. T. A., Oyen W. J. G., PET-CT for radiotherapy treatment planning and response monitoring in solid tumors. Nature Reviews Clinical Oncology 2011 8 4 233 242 2-s2.0-79953246005 10.1038/nrclinonc.2010.218
32. Corry J., Rischin D., Hicks R. J., Peters L. J., The role of PET-CT in the management of patients with advanced cancer of the head and neck. Current Oncology Reports 2008 10 2 149 155 2-s2.0-40849100264 10.1007/s11912-008-0023-x (Pubitemid 351395475)
33. Grégoire V., Haustermans K., Geets X., Roels S., Lonneux M., PET-based treatment planning in radiotherapy: a new standard? Journal of Nuclear Medicine 2007 48 1, supplement 68S 77S 2-s2.0-33947574383 (Pubitemid 47604944)
34. Naumov G. N., Folkman J., Straume O., Tumor dormancy due to failure of angiogenesis: role of the microenvironment. Clinical and Experimental Metastasis 2009 26 1 51 60 2-s2.0-58849107096 10.1007/s10585-008-9176-0
35. Aguirre-Ghiso J. A., Models, mechanisms and clinical evidence for cancer dormancy. Nature Reviews Cancer 2007 7 11 834 846 2-s2.0-35548936833 10.1038/nrc2256 (Pubitemid 350006258)
36. Almog N., Molecular mechanisms underlying tumor dormancy. Cancer Letters 2010 294 2 139 146 2-s2.0-77953362501 10.1016/j.canlet.2010.03.004
37. Pantel K., Alix-Panabières C., Riethdorf S., Cancer micrometastases. Nature Reviews Clinical Oncology 2009 6 6 339 351 2-s2.0-68549137924 10.1038/nrclinonc.2009.44